ViiV CEO: "We Aim To Be Top HIV Player By Mid-2020s"
Executive Summary
ViiV CEO predicts strong pipeline and two-drug strategy will reinforces group's HIV market position and put it ahead of Gilead by the mid-2020s.
You may also be interested in...
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy
The latest drug development news and highlights from our FDA Performance Tracker.
ViiV/Janssen's Long-Acting Anti-HIV Injections Impress
A dual regimen consisting of long-acting injectable formulations of the integrase inhibitor cabotegravir and the nnRTI rilpivirine was as effective as the oral standard-of-care regimen of three drugs daily, in interim results from the ATLAS study.